Autonomix received patent rights from the EPO

Announcement

Autonomix Medical, Inc., a known medical device company devoted to modernising the accurate nerve-focused treatments, have received an official patent right from the European Patent Office (EPO) with the Patent No. EP4230133 with the title ‘Controlled and Precise Treatment of Cardiac Tissues’ to be highlighted in the official records, presenting the company’s all services in an ethical form.

This new 133 patent grant covers methods, devices and systems that identify cardiac/autonomic signals, then aim the target and serve appropriate therapy with a closed-loop response. It's essential to accurately cure the cardiac tissues' conditions by implementing the feedback-powered denervation, neuromodulation and/or ablation of tissues.

This patent right will build confidence in the efforts and the operations the company is striving for. With this, Autonomix will fuel business growth and build trust among the healthcare sector and providers. This is a first stepping stone towards the success of the company to further cherish the future endeavours in its development and advancement.

CEO of Autonomix, Brad Hauser, said, “This European patent marks one more feather to our efforts to expand and bolster the worldwide IP foundation behind our groundbreaking technology platform. This patent is formed on and has met the broadest space for the protection served by our currently issued U.S. Patent No. 12,369,852, which further improves our potential to serve best-in-class, accurate nerve-targeted therapies.”

“The therapies that hold the power to transform treatment in major elevating zones of cardiology involving arrhythmia management, refractory angina, heart failure, and renal denervation for hypertension while cutting off the complications of stress.”

Characterisation of ‘133 patent

The 133 patent is associated with the devices, methods, and systems the company have equipped in their operation to perform precise treatment, navigating and/or testing of tissues and further localise, address, navigate and monitor neural signals near the focused regions. The patent spotlights applications throughout ischemia/angina with refractory angina pain, myocardial infarction risk modulation, and hypertension, including interplay with renal-cardiac nerves.

Including arrhythmias (atrial and ventricular), heart failure, plaque/inflammation modulation and coronary spasm. These conditions are all areas where general feedback-driven modification and denervation can mitigate the dependency on systemic beta blockade and its potential impact.

The company’s first-ever and top-notch technology nominated a platform with the ability to identify infinite indications in various necessary therapeutic spaces involving gastrointestinal disorders, interventional pain management, cardiology, and high blood pressure or resistant hypertension.